

Heinrich Kovar

List of Publications by Citations

Source: <https://exaly.com/author-pdf/896727/heinrich-kovar-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55
papers

5,562
citations

32
h-index

61
g-index

61
ext. papers

6,501
ext. citations

10.8
avg, IF

5.26
L-index

#	Paper	IF	Citations
55	Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. <i>Nature</i> , 1992 , 359, 162-5	50.4	1517
54	MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. <i>Cancer</i> , 1991 , 67, 1886-93	6.4	568
53	Ewing's sarcoma family of tumors: current management. <i>Oncologist</i> , 2006 , 11, 503-19	5.7	361
52	Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3036-46	2.2	356
51	Ewing sarcoma. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 5	51.1	255
50	EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 5324-9	11.5	228
49	A molecular function map of Ewing's sarcoma. <i>PLoS ONE</i> , 2009 , 4, e5415	3.7	135
48	Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. <i>Cell Reports</i> , 2015 , 10, 1082-95	10.6	129
47	DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. <i>Nature Medicine</i> , 2017 , 23, 386-395	50.5	128
46	Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. <i>Oncogene</i> , 1997 , 15, 2225-32	9.2	126
45	Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. <i>Nature Genetics</i> , 2012 , 44, 323-7	36.3	124
44	Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. <i>Cancer Research</i> , 2006 , 66, 9937-47	10.1	117
43	Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. <i>Human Pathology</i> , 2012 , 43, 1300-7	3.7	98
42	EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. <i>Cancer Research</i> , 2008 , 68, 7100-9	10.1	85
41	Dr. Jekyll and Mr. Hyde: The Two Faces of the FUS/EWS/TAF15 Protein Family. <i>Sarcoma</i> , 2011 , 2011, 837-44	3.74	81
40	Ewing's sarcoma and peripheral primitive neuroectodermal tumors after their genetic union. <i>Current Opinion in Oncology</i> , 1998 , 10, 334-42	4.2	76
39	Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. <i>Genome Research</i> , 2013 , 23, 1797-809	9.7	75

38	Detection of tumour cells in peripheral blood and bone marrow from Ewing tumour patients by RT-PCR. <i>International Journal of Cancer</i> , 1995 , 64, 135-9	7.5	72
37	Context matters: the hen or egg problem in Ewing's sarcoma. <i>Seminars in Cancer Biology</i> , 2005 , 15, 189-96	7	71
36	EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. <i>Oncogene</i> , 2005 , 24, 2512-24	9.2	69
35	Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells. <i>Blood</i> , 2012 , 120, 5199-208	2.2	59
34	Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. <i>Cancer Research</i> , 2010 , 70, 4015-23	10.1	54
33	Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma. <i>Clinical Cancer Research</i> , 2010 , 16, 3769-78	12.9	52
32	Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. <i>Oncotarget</i> , 2017 , 8, 34141-34163	3.3	52
31	Synthetic lethality between the cohesin subunits and in diverse cancer contexts. <i>ELife</i> , 2017 , 6,	8.9	50
30	Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. <i>Cancer Research</i> , 2014 , 74, 6578-88	10.1	50
29	Downstream EWS/FLI1 - upstream Ewing's sarcoma. <i>Genome Medicine</i> , 2010 , 2, 8	14.4	48
28	The Ewing family of tumors and the search for the Achilles Heel. <i>Current Opinion in Oncology</i> , 1999 , 11, 275-84	4.2	47
27	Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 1315-28	6.4	40
26	The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease. <i>Oncotarget</i> , 2016 , 7, 8613-24	3.3	38
25	Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. <i>Cancer Research</i> , 2002 , 62, 4583-7	10.1	38
24	Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs. <i>Epigenetics</i> , 2014 , 9, 1613-25	5.7	36
23	EWS-FLI1 employs an E2F switch to drive target gene expression. <i>Nucleic Acids Research</i> , 2015 , 43, 2780-90	10.1	32
22	The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis. <i>Cells</i> , 2020 , 9,	7.9	28
21	Notch signalling is off and is uncoupled from HES1 expression in Ewing's sarcoma. <i>Journal of Pathology</i> , 2011 , 225, 353-63	9.4	27

20	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. <i>Nature Communications</i> , 2018 , 9, 3184	17.4	25
19	EWS-FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex. <i>Nucleic Acids Research</i> , 2019 , 47, 9619-9636	20.1	23
18	Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	23
17	YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. <i>Oncotarget</i> , 2015 , 6, 37678-94	3.3	21
16	EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells. <i>Oncotarget</i> , 2017 , 8, 24679-24693	3.3	18
15	Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation. <i>Cell Death and Disease</i> , 2016 , 7, e2419	9.8	16
14	NPM/ALK gene fusion transcripts identify a distinct subgroup of null type Ki-1 positive anaplastic large cell lymphomas. <i>British Journal of Haematology</i> , 1996 , 92, 866-71	4.5	15
13	YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. <i>Oncogenesis</i> , 2021 , 10, 2	6.6	15
12	Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 88-101	6.1	13
11	The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma. <i>Oncotarget</i> , 2017 , 8, 10980-10993	3.3	12
10	High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. <i>Gene</i> , 2017 , 596, 137-146	3.8	11
9	C/EBP β promotes transformation and chemoresistance in Ewing sarcoma cells. <i>Oncotarget</i> , 2017 , 8, 26013-26026	3.3	11
8	EWS-FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway. <i>FEBS Letters</i> , 2016 , 590, 2063-75	3.8	9
7	ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma. <i>Cell Reports</i> , 2019 , 29, 104-117.e4	10.6	7
6	Selective enhancer changes in osteosarcoma lung metastasis. <i>Nature Medicine</i> , 2018 , 24, 126-127	50.5	7
5	Mechanisms, Diagnosis and Treatment of Bone Metastases. <i>Cells</i> , 2021 , 10,	7.9	7
4	Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers. <i>Oncotarget</i> , 2018 , 9, 31018-31031	3.3	3
3	AURKA inhibitors: right in time. <i>Pediatric Blood and Cancer</i> , 2010 , 55, 3-4	3	2

2	Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma. <i>PLoS ONE</i> , 2020 , 15, e0237792	3.7	2
1	SLFN11: AchillesHeel or Troublemaker. <i>Clinical Cancer Research</i> , 2015 , 21, 4033-4	12.9	